Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Dingli

Showing results (431-440 of 471) with videos related to

Pageof 48
Sort By:
American Journal of Hematology|October 28, 2021
Prognostic significance of acquired 1q22 gain in multiple myelomaHadiyah Y Audil, Joselle M Cook, Patricia T Greipp, et al.
Blood Cancer Journal|March 5, 2021
MASS-FIX for the detection of monoclonal proteins and light chain N-glycosylation in routine clinical practice: a cross-sectional study of 6315 patientsPatrick W Mellors, Surendra Dasari, Mindy C Kohlhagen, et al.
Blood|September 12, 2022
Risk factors for severe infection and mortality in COVID-19 and monoclonal gammopathy of undetermined significanceMatthew Ho, Saurabh Zanwar, Francis K Buadi, et al.
Blood Advances|June 29, 2019
Impact of acquired del(17p) in multiple myelomaArjun Lakshman, Utkarsh Painuly, S Vincent Rajkumar, et al.
Blood Cancer Journal|December 27, 2025
Impact of t(11;14) primary cytogenetic abnormality and the cumulative effect of multiple high-risk cytogenetics at diagnosis on the outcomes of patients with primary plasma cell leukemiaTamer Hellou, Shaji K Kumar, Samhar Samer Alouch, et al.
Leukemia|March 24, 2018
Prognostic significance of interphase FISH in monoclonal gammopathy of undetermined significanceArjun Lakshman, Shilpa Paul, S Vincent Rajkumar, et al.
American Journal of Hematology|June 4, 2026
Patterns of Progression and Clinical Outcomes After First Progression in Patients With Primary Plasma Cell LeukemiaDaniel G Packard, Shaji K Kumar, Angela Dispenzieri, et al.
Blood Cancer Journal|March 9, 2019
Natural history of multiple myeloma with de novo del(17p)Arjun Lakshman, Utkarsh Painuly, S Vincent Rajkumar, et al.
Bone|March 18, 2010
A promising approach for treatment of tumor-induced bone diseases: utilizing bisphosphonate derivatives of nucleoside antimetabolitesMonica M Reinholz, Shawn P Zinnen, Amylou C Dueck, et al.
American Journal of Hematology|October 13, 2022
Risk factors for severe infection and mortality In patients with COVID-19 in patients with multiple myeloma and AL amyloidosisMatthew Ho, Saurabh Zanwar, Francis K Buadi, et al.
Pageof 48

Showing results (431-440 of 471) with videos related to

Sort By:
Pageof 48
American Journal of Hematology|October 28, 2021
Prognostic significance of acquired 1q22 gain in multiple myelomaHadiyah Y Audil, Joselle M Cook, Patricia T Greipp, et al.
Blood Cancer Journal|March 5, 2021
MASS-FIX for the detection of monoclonal proteins and light chain N-glycosylation in routine clinical practice: a cross-sectional study of 6315 patientsPatrick W Mellors, Surendra Dasari, Mindy C Kohlhagen, et al.
Blood|September 12, 2022
Risk factors for severe infection and mortality in COVID-19 and monoclonal gammopathy of undetermined significanceMatthew Ho, Saurabh Zanwar, Francis K Buadi, et al.
Blood Advances|June 29, 2019
Impact of acquired del(17p) in multiple myelomaArjun Lakshman, Utkarsh Painuly, S Vincent Rajkumar, et al.
Blood Cancer Journal|December 27, 2025
Impact of t(11;14) primary cytogenetic abnormality and the cumulative effect of multiple high-risk cytogenetics at diagnosis on the outcomes of patients with primary plasma cell leukemiaTamer Hellou, Shaji K Kumar, Samhar Samer Alouch, et al.
Leukemia|March 24, 2018
Prognostic significance of interphase FISH in monoclonal gammopathy of undetermined significanceArjun Lakshman, Shilpa Paul, S Vincent Rajkumar, et al.
American Journal of Hematology|June 4, 2026
Patterns of Progression and Clinical Outcomes After First Progression in Patients With Primary Plasma Cell LeukemiaDaniel G Packard, Shaji K Kumar, Angela Dispenzieri, et al.
Blood Cancer Journal|March 9, 2019
Natural history of multiple myeloma with de novo del(17p)Arjun Lakshman, Utkarsh Painuly, S Vincent Rajkumar, et al.
Bone|March 18, 2010
A promising approach for treatment of tumor-induced bone diseases: utilizing bisphosphonate derivatives of nucleoside antimetabolitesMonica M Reinholz, Shawn P Zinnen, Amylou C Dueck, et al.
American Journal of Hematology|October 13, 2022
Risk factors for severe infection and mortality In patients with COVID-19 in patients with multiple myeloma and AL amyloidosisMatthew Ho, Saurabh Zanwar, Francis K Buadi, et al.
Pageof 48